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SUMMARY
Objective: Benign epilepsy with centrotemporal spikes (BECTS) is a common, self-
limited epilepsy syndrome affecting school-age children. Classic interictal epileptiform
discharges (IEDs) confirm diagnosis, and BECTS is presumed to be pharmacorespon-
sive. As seizure risk decreases in timewith this disease, we hypothesize that the impact
of IEDs and anticonvulsive drug (ACD) treatment on the risk of subsequent seizure will
differ based on disease duration.
Methods: We calculate subsequent seizure risk following diagnosis in a large retro-
spective cohort of children with BECTS (n = 130), evaluating the impact of IEDs and
ACD treatment in the first, second, third, and fourth years of disease. We use a
Kaplan–Meier survival analysis and logistic regression models. Patients were censored
if they were lost to follow-up or if they changed group status.
Results: Two-thirds of children had a subsequent seizure within 2 years of diagnosis.
The majority of children had a subsequent seizure within 3 years despite treatment.
The presence of IEDs on electroencephalography (EEG) did not impact subsequent
seizure risk early in the disease. By the fourth year of disease, all children without IEDs
remained seizure free, whereas one-third of children with IEDs at this stage had a sub-
sequent seizure. Conversely, ACD treatment corresponded with lower risk of seizure
early in the disease but did not impact seizure risk in later years.
Significance: In this cohort, the majority of children with BECTS had a subsequent sei-
zure despite treatment. In addition, ACD treatment and IEDs predicted seizure risk at
specific points of disease duration. Future prospective studies are needed to validate
these exploratory findings.
KEY WORDS: Benign epilepsy with centrotemporal spikes, Interictal epileptiform
discharges, Treatment, Biomarker, Seizure risk.
Benign epilepsy with centrotemporal spikes (BECTS) is
a common childhood epilepsy syndrome, accounting for
10–15% of all childhood epilepsies and characterized by a
transient period of seizure susceptibility in school-age chil-
dren.1–5 Although nearly all children will enter remission
spontaneously by age 18, there are no reliable clinical pre-
dictors for when remission will occur in an individual
child.6 Fifteen percent of children with BECTS will have
only a single seizure, two-thirds will have 2–5 seizures, and
still others have recurrent seizures over several years.6,7
Interictal epileptiform discharges (IEDs) on electroen-
cephalography (EEG) are a well-characterized electrical
feature for diagnosis in BECTS8,9 and the most clinically
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useful biomarker to identify the risk of a second seizure in
idiopathic childhood epilepsy in general.10,11 In population
studies, IEDs are highly specific for epilepsy, present in
only 0.5–2.4% of the general population.12–14 IEDs also
help stratify risk of subsequent seizure after drug taper in
the general epilepsy population.15 Whether the presence of
IEDs at different stages of disease predicts seizure risk in a
self-limited epilepsy syndrome, such as BECTS, is not
known.
Given the uncertainty in individual seizure risk, there is
wide variability in treatment strategies for BECTS. Most
practitioners favor treatment of most children with anticon-
vulsant drugs (ACDs) until at least 1–2 years after their last
clinical seizure, although there is much debate regarding the
optimal approach due to competing concerns regarding sei-
zure risk and ACD side-effects.16–21 Given the diminishing
risk of seizure over time in BECTS, it follows that the bene-
fits of ongoing ACD exposure over the course of the disease
could decrease in a similar fashion, although this has not
been previously evaluated.
We hypothesized that the impact of IEDs and ACD treat-
ment on the risk of subsequent seizure differs based on dis-
ease duration in BECTS. To study this, we evaluated the
risk of subsequent seizure in a large retrospective popula-
tion of children with BECTS following initial diagnosis.
We evaluated whether IEDs and ACD treatment predict
subsequent seizure risk in each of the first 4 years of the dis-
ease.
Methods
Subjects
All patients seen at Massachusetts General Hospital
(MGH) between June 2001 and June 2017 with a clinical
diagnosis of BECTS made by a child neurologist, an EEG
report that captured sleep, and sufficient clinical data to
determine seizure course were included. Patients were iden-
tified via search of our institution’s EEG database of EEG
reports containing the words “rolandic,” “sleep-activated,”
“sleep activated,” “benign,” “BECTS,” “ECTS,”
“centrotemporal,” “centro-temporal,” or “horizontal
dipole,” Patients were required to have had at least one clini-
cal seizure characterized by a focal motor seizure or secon-
darily generalized convulsive seizure and an EEG showing
sleep-activated centrotemporal spikes, consistent with the
1989 International League Against Epilepsy (ILAE) elec-
troclinical diagnosis of BECTS used in previous prospective
and large retrospective studies.1,3,6,22 Although the 1989
ILAE diagnostic criteria for BECTS include seizure onset
between 3 and 13 years,23 several prospective studies and a
large retrospective meta-analysis have found that children
that otherwise meet criteria for BECTS can present during
infancy and toddler years,3,4,6,7,24–26 and the inclusion cut-
off at 3 years may inaccurately describe this disease. Here,
we have included children with age at onset younger than
3 years. Most of the screened subjects that were excluded
did not meet electroclinical criteria for BECTS and were not
diagnosed with BECTS. Rarely, subjects were excluded
because (1) the subject had an EEG study that was consis-
tent with BECTS and was diagnosed by a provider with
BECTS but had no documented clinical seizure; (2) the sub-
ject had an EEG study that was consistent with BECTS but
no documented clinic visit at our institution; or (3) the sub-
ject had a comorbid diagnosis of symptomatic abnormal
brain magnetic resonance imaging (MRI), abnormal neuro-
logic examination findings, or an unrelated genetic disease.
Twenty-five subjects who met electroclinical criteria for
BECTS were excluded because they did not have an EEG
that captured sleep. We note that although we required all
subjects to have an EEG that included sleep to improve the
sensitivity to capture spikes,27,28 EEG reports did not reli-
ably distinguish between centrotemporal spikes captured
during wakefulness, sleep, or both. Patients with clinical
features consistent with BECTS but initial EEG without
classic findings were included if subsequent EEG showed
centrotemporal spikes. Chart review was performed to col-
lect the clinical variables of interest through the duration of
documented follow-up at our institution: age at EEG in
months, the presence of IEDs on EEG, presence of atypical
findings on EEG (generalized or focal background slowing,
generalized spike-and-wave discharges, non-centrotem-
poral focal IEDs, and other findings), ACD status and dose,
date of the first known seizure, and date of the most recent
seizure following the EEG. A total of 130 unique patients
(ages 0.6–13.4 years at first known seizure, mean =
7.6 years, median = 8.0 years) met inclusion criteria. From
the 130 patients, 216 EEG studies obtained from the first,
second, third, and fourth years of disease were evaluated.
For each year of analysis, only one EEG (the first EEG
obtained during the defined year) for each individual was
included. Each year of analysis was evaluated based on sta-
tus during that time period of interest, independent of status
in prior years (e.g., year 2 analysis followed patient treat-
ment status and seizure risk from year 2 on, independent of
prior treatment status and seizure history in year 1). When
Key Points
• The impact of medication and IEDs on seizure risk
depends on the duration of disease in BECTS
• Medication lowers the risk of seizure in the first year,
but does not affect seizure risk in subsequent years
• Although presumed pharmacoresponsive, more than
half of children treated with medication from presen-
tation had a subsequent seizure
• IEDs do not predict seizure risk in the first 3 years,
but the absence of IEDs in the fourth year may indicate
remission
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all time points were evaluated together, all EEG recordings
were studied.
Analysis
Seizure risk was analyzed using Kaplan-Meier survival
analysis and significance was computed using a log-rank
test.29 Results are reported with 95% confidence intervals
(CIs) and figures displayed as Kaplan-Meier survival curves
with the cumulative probability of seizure recurrence plot-
ted as a function of time from the first EEG obtained in the
first, second, third, and fourth years of disease.
We report the risk of subsequent seizure from the time at
EEG and compare the impact of IEDs and ACD treatment
on subsequent seizure risk. To assess seizure risk at different
stages of this disease, we evaluate the impact of IEDs and
ACD treatment on subsequent seizure risk following EEG
recordings obtained in the first year of disease and following
EEG recordings obtained each year through the fourth year
after diagnosis. Because the delay between first seizure and
time to EEG and duration of follow-up could each introduce
a temporal bias in this age-specific syndrome, we evaluated
the significance of this delay between groups using a Mann-
Whitney test. Unless noted in the text, for all group compar-
isons, there was no difference between the median time
from first seizure to EEG or duration of follow-up between
groups (p > 0.05 for all comparisons, Table S1).
Patients were censored if they were lost to follow-up or if
they changed group status (e.g., switched from off ACDs to
on ACDs). Time to event was measured by the number of
months between the EEG and when the patient was cen-
sored. We defined a patient’s medication status as on or off
ACDmedication, excluding changes that lasted for less than
1 month. A patient was categorized as lost to follow-up if
they did not have a seizure at the time of the last available
clinic note or at the time of a medication status change.
To test for an association between clinical and EEG fea-
tures and subsequent seizure risk, we also built a logistic
regression model of seizure risk and tested the predictors:
ACD treatment, IED, age at onset, and atypical EEG find-
ings. To account for censoring, we included duration of fol-
low-up as a predictor in each model. For each analysis, we
initially tested the predictor variable of interest, added sub-
sequent variables, and evaluated model quality using
Akaike information criterion (AIC).30
Results
Overall risk of seizure in BECTS
The risk of a subsequent seizure in children with BECTS
was high following diagnosis (n = 107 subjects, Fig. 1).
Approximately one-third of subjects (31.7%, 95% CI 21.7–
40.4%) had a subsequent seizure within 6 months; one-half
of subjects (46.4, 95% CI 34.9– 55.8%) had a subsequent
seizure within 12 months; and two-thirds of subjects
(60.7%, 95% CI 48.2–70.2%) had a subsequent seizure
within 2 years. After 2 years without seizure following ini-
tial diagnosis, the risk of subsequent seizure was very low;
only 3.3% and 5.1% of children had a subsequent seizure
within 12 months after 2 and 3 years without seizure,
respectively. In this cohort, the median time to first EEG
after first clinical seizure was 1.0 month (range 0–
11 months). The median duration of follow-up was
17.5 months (range 0–103 months). The risk for subsequent
seizure was not affected by whether patients had more than
one seizure prior to EEG (n = 58) compared to those who
had only a single seizure prior to EEG (n = 49, p = 0.56).
IEDs as a biomarker for seizure risk in BECTS
To determine whether interictal epileptiform spikes could
serve as a biomarker for ongoing seizure risk in this disease,
we evaluated the risk of subsequent seizures in children
based on whether IEDs were present on their most recent
EEG study. Among all subjects and all EEG data available,
there was no difference in subsequent seizure risk based on
the presence (n = 174) or absence of IEDs (n = 42) on the
most recent EEG recording (p = 0.23). We note that, con-
sistent with our hypothesis, the duration of time from first
seizure to EEG was longer in the group without IEDs
(p = 0.0002, Table S1). We subsequently evaluated the util-
ity of this biomarker based on disease duration, below.
IEDs do not predict seizure risk in the first 3 years in
BECTS
We found no difference in subsequent seizure risk based
on the presence (n = 94) or absence of IEDs (n = 13) on the
first EEG obtained after presentation (p = 0.94; Fig. 2A).
Similarly, the presence (n = 38, n = 29) or absence (n = 9,
n = 10) of IEDs on EEG obtained in the second or third year
of disease did not predict subsequent seizure risk (p = 0.98,
p = 0.64, respectively). We note that the second year cohort
of children with IEDs on EEG had a longer duration of fol-
low-up compared to those without IEDs (p = 0.02,
Table S1); because longer follow-up would increase the
likelihood of capturing a subsequent seizure, and this was
not observed, we do not expect this difference to affect the
interpretation of our results.
Absence of IEDs may indicate remission in BECTS in later
years of disease
During the fourth year of disease, no child without
IEDs on EEG (n = 10) had a subsequent seizure. How-
ever, approximately one-third of children for whom
EEG captured IEDs (n = 13) at this stage of disease
had a seizure over the subsequent 18 months of obser-
vation (31.3%, 95% CI 0–61.9%). Using a log-rank test,
the difference in seizure risk between the 2 groups was
not statistically significant (p = 0.16) but was limited by
small sample size. In the fourth year, the positive pre-
dictive value of IEDs to predict subsequent seizure was
0.31; however, the negative predictive value of IEDs to
Epilepsia Open, 3(3):409–417, 2018
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predict subsequent seizure was high at 1.0. The survival
curve for this cohort, separated by whether IEDs were
observed on the EEG, is shown in Figure 2C. The
cumulative risk of subsequent seizure based on the pres-
ence or absence of IEDs for each year evaluated is
summarized in Table 1.
ACD treatment modified seizure risk in BECTS early
but not late in disease course
Among all subjects, at all time points, we found no
difference in seizure risk between children treated with
ACDs (n = 120) and children not treated with ACDs
(n = 96, p = 0.80). We further evaluated the impact of
ACD treatment on seizure risk throughout the disease
course.
ACDs lower but do not eliminate seizure risk if started in the
first year in BECTS
Children in whom ACD treatment was initiated early in
the disease course (n = 53) had a lower risk of seizure com-
pared to children not treated (n = 54; p = 0.03; Fig. 3A),
and the majority of this benefit was achieved early. When
initiated after the first EEG, ACD treatment was associated
with a reduction in subsequent seizure risk by 17.9% and
26.2% at 12 months and 24 months, respectively. Although
seizure risk was reduced with ACD treatment, it was not
eliminated and the risk of seizure remained high in both
groups; 38.3% of children (95% CI 23–50.5%) treated with
ACD had a seizure within 12 months compared to 56.1% of
children (95% CI 37.4–69.3%) who were not treated. Of
those for whom treatment was initiated early and
Figure 1.
Seizure risk following electroclinical diagnosis. A, Results are displayed as a Kaplan-Meier survival curve (95% CI) with the cumulative
probability of seizure recurrence plotted as a function of time from first EEG. Seizure risk follows an exponential curve, where approxi-
mately one-third of children have a subsequent seizure within 6 months, one-half within 12 months, and two-thirds within 2 years. B,
Risk of seizure recurrence computed from a logistic regression model following initial EEG (dashed lines indicate 95% CI computed from
a bootstrap resampling procedure).
Epilepsia Open ILAE
Figure 2.
Impact of interictal epileptiform discharges (IEDs) on seizure risk. A, There is no difference in subsequent seizure risk based on the pres-
ence or absence of IEDs on the first EEG after initial presentation (p = 0.94). B, Risk of seizure recurrence computed from a logistic
regression model following initial EEG based on the presence (red) or absence (blue) of IEDs (dashed lines indicate 95% CI computed
from a bootstrap resampling procedure); IEDs do not correlate with seizure risk. C, Following EEG obtained in the fourth year of disease,
all children without IEDs on EEG remained seizure-free, whereas approximately one-third of those with IEDs had a subsequent seizure.
Epilepsia Open ILAE
Epilepsia Open, 3(3):409–417, 2018
doi: 10.1002/epi4.12248
412
W. Xie et al.
maintained, 55.8% (95% CI 33.1–70.8%) had a seizure
within 36 months compared to 74.7% (95% CI 54.9–
85.7%) of those never treated.
ACDs do not lower seizure risk after the first year in BECTS
Among children who underwent EEG evaluation in the
second, third, and fourth years of disease, we found no
difference in seizure risk among those treated with ACDs
(n = 32, 26, 9) compared to those not treated (n = 15,
13, 14; p = 0.75, 0.34, 0.38, respectively). As expected
with the natural history of this disease, there was a lower
overall risk of subsequent seizure in later years of the
disease. In the second year of disease, the risk of subse-
quent seizure in the untreated group was 35.4% at
12 months (95% CI 4.5–56.2%), which was comparable
to the risk in those that received ACD treatment in the
same time period 41.8% (95% CI 21.4–56.9%, Fig. 3C).
By 24 months of follow-up, more than half of treated
and untreated children had a subsequent seizure (51.7%
treated, 95% CI 28.1–67.5%; 51.5% untreated 95% CI
15.2–72.3%). In the third year, approximately one-third
of treated and untreated children (35.4% treated, 95% CI
12.1–52.5%; 35.8% untreated, 95% CI 0.35–58.7%) had
a seizure within 6 months of follow-up. Following an
EEG in the fourth year of disease, 12.5% (95% CI 0.0–
32.7%) of both treated and untreated children had a sub-
sequent seizure within 24 months of follow-up. We note
that in the fourth year cohort, the duration of follow-up
was longer for children not treated with ACDs compared
to those treated (p = 0.04, Table S1), but do not expect
this difference to impact the interpretation of the find-
ings, which were also evident in the second- and third-
year cohorts who had comparable durations of follow-up.
The cumulative risk of subsequent seizure for treated and
Table 1. Cumulative seizure risk over time by cohort
Year Feature No. of children 3-month seizure risk (%) 6-month seizure risk (%) 12-month seizure risk (%)
1 ACD 53 19.20 29.47 33.26
No ACD 54 26.30 33.67 56.11
IED 94 22.6 31.77 46.26
No IED 13 23.8 30.77 46.15
2 ACD 32 31.25 34.52 41.80
No ACD 15 13.33 20.00 35.35
IED 38 26.32 31.58 42.98
No IED 9 22.22 22.22 22.22
3 ACD 26 26.15 35.38 49.74
No ACD 13 35.83 35.83 35.83
IED 29 34.05 34.05 43.10
No IED 10 14.29 28.57 52.38
4 ACD 9 12.50 12.50 12.50
No ACD 14 0 0 0
IED 13 8.33 8.33 8.33
No IED 10 0 0 0
Figure 3.
Impact of ACDs on seizure risk following all EEG studies. A, Children treated with ACDs at the time of the first EEG (blue) had a lower
risk of subsequent seizure compared to those not treated (red, p = 0.03); however, more than half of treated children still had a subse-
quent seizure. B, Risk of subsequent seizure computed from a logistic regression model following initial EEG based on the absence (red)
or presence (blue) of ACD treatment (dashed lines indicate 95% CI computed from a bootstrap resampling procedure); ACD treatment
started in the first year is associated with a decreased risk of subsequent seizure (p = 0.03). (C) There was no difference in seizure risk
between treated and untreated children in the second year of disease (shown here) or any subsequent year evaluated (not shown).
Epilepsia Open ILAE
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untreated children for each year evaluated is summarized
in Table 1.
Impact of atypical EEG findings on risk of seizure in
BECTS
We explored the risk of subsequent seizure between chil-
dren with at least one atypical finding on EEG (n = 25),
only typical findings on EEG (e.g., centrotemporal spikes,
n = 73), and normal EEG (n = 9) at diagnosis. Atypical
EEG findings observed in our cohort included generalized
background slowing (n = 3), focal background slowing
(n = 9), generalized spike-and-wave complexes (n = 4),
non-centrotemporal spikes (n = 12), and other (n = 1,
Table 2). There was no difference in subsequent seizure risk
between groups (p = 0.87, Fig. 4).
Logistic regression models support empirical findings
To further examine the association between our features
of interest and seizure risk, we built a logistic regression
model of seizure risk and tested the predictors: time since
EEG, ACD treatment, presence of IEDs, age at onset, and
atypical EEG findings. As expected, following the first
EEG, time since EEG was a significant predictor of seizure
risk, where there was a decreased risk of seizure over time
(p = 0.0006), such that there is a 5% reduction in the odds
of seizure with each subsequent seizure-free month.
Consistent with our empirical results, in a multivariate
model using duration of follow-up and the presence of IEDs
as predictors, we found that the presence of IEDs did not
correlate with seizure risk in the first, second, or third years
of disease (p > 0.5 for all tests; Fig. 2B). Adding ACDs as a
predictor did not impact these results (p > 0.5 for all tests).
In the fourth year, because the absence of IEDs was a perfect
predictor of no further seizures, maximum likelihood esti-
mates for the effect of this predictor result in an estimated
odds ratio of 0, but the significance of this effect cannot be
computed by assuming approximate normality. However,
when computing a Bayesian confidence interval we found
that the probability that the absence of IEDs in the fourth
year decreases seizure risk was 77%. Thus, the absence of
spikes in the fourth year likely indicates decreased seizure
risk.
Consistent with the empirical results, using a logistic
regression model with ACD treatment status and duration of
follow-up as predictors, we found that ACD treatment
started in the first year of disease is associated with a
decreased risk of subsequent seizure (p = 0.03; Fig. 3B).
The odds ratio of having a subsequent seizure is 0.53 when
treated with ACDs started in the first year of disease. We
found no effect of ACD treatment on seizure risk in the sec-
ond, third, or fourth years of disease (p > 0.05 for all tests).
We further evaluated for an association between risk of
seizure and age at first seizure, atypical EEG features, and
number of ACDs beyond one. We found that for all data,
there was no association between any of these predictors
and seizure risk (p > 0.05 for all tests). In all of the above
models tested, adding these predictors increased the AIC,
thereby decreasing model quality.
Discussion
Although the electroclinical features for diagnosis in
BECTS are stereotyped, the seizure course is highly vari-
able across children, limiting the accuracy of the prognostic
information available for any individual case. Here we eval-
uate a large retrospective cohort of children with BECTS to
better characterize the seizure course and provide improved
data to guide counseling discussions and treatment consid-
erations. Because the risk of seizure decreases with time, we
evaluated the impact of IEDs and ACD treatment on the risk
of subsequent seizure at different stages in the disease
Table 2. Atypical EEG features in children with BECTS
Atypical finding No. of children
Extra-rolandic spikes 16
Occipital 3
Frontal 3
Temporal 2
Parietal 1
Midline 1
Multifocal 2
Generalized 4
slowing 12
Hemispheric 5
Occipital 3
Frontal 1
Generalized 4
Sharp alpha 1
Any atypical finding 25
Figure 4.
Impact of atypical EEG findings on subsequent seizure risk in
BECTS. There was no difference in seizure risk between children
who had normal EEG findings, typical centrotemporal spikes, or
atypical findings on EEG at diagnosis.
Epilepsia Open ILAE
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course. We found that neither the presence of IEDs early in
the disease nor atypical features on the EEG impact the risk
of subsequent seizure; however, the absence of IEDs late in
disease may indicate remission. We also found that treat-
ment with ACDs early in the course of the disease reduces,
but does not eliminate, the risk of seizure. After the first year
of disease, ACD treatment did not significantly impact sei-
zure risk.
These findings have several implications. First, BECTS
is described as a pharmacoresponsive epilepsy syndrome,
where children are expected to rapidly respond to anticon-
vulsant medication treatment.8,9 However, this observation
is confounded by the self-limited nature of the disease, and
no class I or class II evidence for medication efficacy cur-
rently exists.31,32 In our cohort, over half of the children fol-
lowed from diagnosis had a subsequent seizure despite
receiving treatment with ACDs. The lack of complete sei-
zure control in these children could indicate poor compli-
ance or that this epilepsy is less pharmacoresponsive than
previously thought. Because quality of life improves most
dramatically in patients with epilepsy who achieve seizure
freedom,33–36 a better understanding of the true pharma-
coresponsiveness of BECTS may influence the risk–benefit
discussion when determining treatment plans with families.
Decisions on the duration of ACD treatment in BECTS
rely on many variables, ranging from concerns of ACD
medication side-effects, to ongoing seizure risk, including
recent attention to the low but present risk of sudden unex-
plained death in these children.18,20,37 We found that initiat-
ing ACD treatment at diagnosis corresponded with a
decreased risk of subsequent seizure. However, after the
first year, ACD treatment did not significantly lower seizure
risk. Although selection bias may have contributed to these
results, our findings are consistent with previous work that
found that the duration of active disease is less than 3 years
for most children with BECTS.6 In addition, a Cochrane
review concluded that evidence supports only short-term
treatment for seizure control in BECTS.32 In our cohort, the
risk of subsequent seizure in untreated children was much
lower in the second year of disease compared to the first,
and continued to decrease for each subsequent year. The
lack of efficacy of ACDs in later years was thus likely influ-
enced by spontaneous remission. These findings suggest
that the diminishing returns of ACD treatment due to the
expected rate of remission should be considered when
weighing treatment options for a particular child.
In a large meta-analysis, the decision to taper ACDs
resulted in at least one seizure in 39% of children with
BECTS.6 Biomarkers to help guide physicians in selecting
who is ready for ACD discontinuation could limit unneces-
sary prolonged drug exposure and reduce discontinuation
failures. A separate meta-analysis evaluating the risk of
ACD discontinuation among all epilepsies found that the
presence of interictal spikes on EEG predicts increased sei-
zure risk.15 Here, we found that this relationship may
depend on disease duration in a self-limited epilepsy syn-
drome. IEDs are poor biomarkers for ongoing seizure risk in
children with BECTS early in disease. This is consistent
with the observation that over 10% of BECTS children have
been reported to still have IEDs on EEG after remission.6
The poor specificity of spikes to identify continued risk in
BECTS has also been shown in kindred studies where clas-
sic centrotemporal IEDs were reported in one-third of sib-
lings of children with BECTS, most of whom did not have
epilepsy.38,39
Notably, we also found that all children without spikes on
EEG during the fourth year of disease course remained sei-
zure free (negative predictive value [NPV] 1.0), suggesting
that that the absence of spikes late in the disease may pro-
vide a reliable, albeit delayed, marker of disease remission.
Although the patient cohort to evaluate this feature was rela-
tively small (n = 10), this result is consistent with data
available from prior work showing that only 1 of 14 children
with BECTS without spikes on EEG late in the disease (year
4 or after) had a subsequent seizure40; combined, these
results suggest that the absence of spikes is a reliable indica-
tor of disease remission. Although this exploratory finding
requires validation in a larger, prospective study, this easy
to obtain biomarker would enable confident identification
of children for whom prolonged ACD therapy is no longer
necessary, thereby curbing unnecessary drug exposure later
in the disease course.
The primary limitation of this study is the retrospec-
tive collection of the data used. Because children require
an EEG for diagnosis of this electroclinical syndrome,
this limitation is unlikely to impact the selection of chil-
dren evaluated early in the disease course. Moreover, the
cumulative seizure risk in our cohort was similar to that
reported from prospective datasets.1,3 However, because
only a subset of children underwent subsequent EEG
evaluations in our study, the cohort of children evaluated
later in the disease course diminished for each year of
analysis and was likely enriched by both those being
evaluated for medication taper due to seizure freedom
and those being followed for more severe seizure course.
Because the most common reason to obtain a late EEG
study in children with BECTS is to guide a medication
taper after a period seizure free, our later cohorts are
most likely to be biased toward a cohort with lower sei-
zure frequency. Thus, the finding that the presence of
EEG spikes is not helpful to guide medication taper in
years 2 and 3 may be particularly relevant to the popula-
tion selected for repeat EEG. These findings, however,
remain preliminary and should be validated in a prospec-
tive population-based study. In addition, we were unable
to control unmeasured factors, such as the presence of
generalized seizures, seizures during wakefulness, ACD
compliance, or other factors that may have contributed to
a practitioner’s decision to use ACDs. A prospective
population-based study with planned EEG and clinical
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follow-up would be required to confirm the observations
reported here.
We also note that we have included children with age at
onset before 3 years of age in this study. To evaluate the
impact of this decision, we evaluated age at onset as a pre-
dictor in our multivariate regression analysis. Consistent
with a prior population-based prospective study,1 we did not
find that age at seizure onset predicted subsequent seizure
risk.
Although BECTS is a common and well-characterized
electroclinical syndrome, reliable biomarkers for seizure
course have not been identified and the impact and necessity
of medication treatment remains controversial. This work
helps to clarify the impact of IEDs and medication treatment
on seizure risk in this electroclinical syndrome. In addition,
this study highlights the importance of evaluating biomark-
ers and clinical risk factors with attention to the disease
duration in age-specific epilepsy syndromes.
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